RecruitingPHASE1, PHASE2NCT04604782

A Study to Evaluate the Safety and Pharmacokinetics of Regadenoson in Pediatric Patients

Studying Cold agglutinin disease

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
GE Healthcare
Principal Investigator
David Thompson, MD, PhD
GE Healthcare
Intervention
Regadenoson(drug)
Enrollment
54 target
Eligibility
18 years · All sexes
Timeline
2021 – 2026

Study locations (5)

Collaborators

Covance

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04604782 on ClinicalTrials.gov

Other trials for Cold agglutinin disease

Additional recruiting or active studies for the same condition.

See all trials for Cold agglutinin disease →

← Back to all trials